InMode (INMD) to Release Earnings on Wednesday

Key Points

• InMode is scheduled to release Q1 2026 results before the market opens on Wednesday, May 6, 2026 at 8:30 AM ET; analysts expect $0.2984 EPS and $79.417 million in revenue.
• In the prior quarter InMode reported $0.46 EPS (beating estimates) and $103.85 million in revenue with revenue up 6.1% year‑over‑year; the stock trades around $14.21 with a market cap near $900 million and a P/E of about 9.9.
• Wall Street consensus is a Hold (one Buy, five Hold, one Sell) with an average target of $17.25, and institutional investors own roughly 68% of the shares amid recent incremental position increases by several funds.

InMode (NASDAQ:INMD - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.2984 per share and revenue of $79.4170 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.

InMode (NASDAQ:INMD - Get Free Report) last announced its earnings results on Tuesday, February 10th. The healthcare company reported $0.46 earnings per share for the quarter, beating analysts' consensus estimates of $0.42 by $0.04. The business had revenue of $103.85 million for the quarter, compared to the consensus estimate of $104.64 million. InMode had a net margin of 25.33% and a return on equity of 14.52%. InMode's quarterly revenue was up 6.1% on a year-over-year basis. During the same period last year, the firm posted $0.42 earnings per share.

InMode Price Performance

Shares of INMD opened at $14.21 on Wednesday. The firm's 50 day simple moving average is $13.86 and its 200 day simple moving average is $14.38. The company has a market capitalization of $900.35 million, a P/E ratio of 9.87 and a beta of 2.12. InMode has a 1-year low of $12.72 and a 1-year high of $16.74.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Deutsche Bank AG grew its position in InMode by 35.9% during the fourth quarter. Deutsche Bank AG now owns 3,927 shares of the healthcare company's stock valued at $58,000 after acquiring an additional 1,037 shares during the last quarter. Quadrant Capital Group LLC grew its position in InMode by 127.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company's stock valued at $29,000 after acquiring an additional 1,091 shares during the last quarter. Inspire Investing LLC grew its position in InMode by 11.7% during the fourth quarter. Inspire Investing LLC now owns 18,255 shares of the healthcare company's stock valued at $268,000 after acquiring an additional 1,917 shares during the last quarter. Van ECK Associates Corp grew its position in InMode by 9.5% during the fourth quarter. Van ECK Associates Corp now owns 22,693 shares of the healthcare company's stock valued at $333,000 after acquiring an additional 1,976 shares during the last quarter. Finally, Parallel Advisors LLC grew its position in InMode by 113.3% during the fourth quarter. Parallel Advisors LLC now owns 4,318 shares of the healthcare company's stock valued at $63,000 after acquiring an additional 2,294 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

INMD has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of InMode in a research note on Thursday, January 22nd. Robert W. Baird set a $17.00 target price on shares of InMode in a research note on Wednesday, February 11th. Finally, BTIG Research reaffirmed a "neutral" rating on shares of InMode in a research note on Monday, January 26th. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $17.25.

InMode Company Profile

InMode Ltd. NASDAQ: INMD is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode's product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.